Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kettner

Showing results (791-800 of 809) with videos related to

Pageof 81
Sort By:
NPJ Precision Oncology|July 27, 2025
IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancerNicole M Kettner, Tuyen N Bui, Juliana Navarro-Yepes, et al.
Nature Communications|May 5, 2026
Human brain changes after first psilocybin useT Lyons, M Spriggs, L Kerkelä, et al.
Nature Communications|July 24, 2019
Towards a standardized bioinformatics infrastructure for N- and O-glycomicsMiguel A Rojas-Macias, Julien Mariethoz, Peter Andersson, et al.
The FEBS Journal|January 14, 2010
Measuring enzyme activities under standardized in vivo-like conditions for systems biologyKaren van Eunen, Jildau Bouwman, Pascale Daran-Lapujade, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2006
1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor XaDonald J P Pinto, Michael J Orwat, Mimi L Quan, et al.
The FEBS Journal|March 5, 2026
Metabolic thermodynamics: pertinent reference state and energy potentialsHans V Westerhoff, Barbara M Bakker, Andreas S Bommarius, et al.
Glycobiology|March 22, 2014
MIRAGE: the minimum information required for a glycomics experimentWilliam S York, Sanjay Agravat, Kiyoko F Aoki-Kinoshita, et al.
Standards in Genomic Sciences|February 10, 2011
Meeting Report from the Second "Minimum Information for Biological and Biomedical Investigations" (MIBBI) workshopCarsten Kettner, Dawn Field, Susanna-Assunta Sansone, et al.
Glycobiology|September 23, 2016
The minimum information required for a glycomics experiment (MIRAGE) project: sample preparation guidelines for reliable reporting of glycomics datasetsWeston B Struwe, Sanjay Agravat, Kiyoko F Aoki-Kinoshita, et al.
Plos One|February 25, 2015
Positive influence of being overweight/obese on long term survival in patients hospitalised due to acute heart failureSimona Littnerova, Jiri Parenica, Jindrich Spinar, et al.
Pageof 81

Showing results (791-800 of 809) with videos related to

Sort By:
Pageof 81
NPJ Precision Oncology|July 27, 2025
IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancerNicole M Kettner, Tuyen N Bui, Juliana Navarro-Yepes, et al.
Nature Communications|May 5, 2026
Human brain changes after first psilocybin useT Lyons, M Spriggs, L Kerkelä, et al.
Nature Communications|July 24, 2019
Towards a standardized bioinformatics infrastructure for N- and O-glycomicsMiguel A Rojas-Macias, Julien Mariethoz, Peter Andersson, et al.
The FEBS Journal|January 14, 2010
Measuring enzyme activities under standardized in vivo-like conditions for systems biologyKaren van Eunen, Jildau Bouwman, Pascale Daran-Lapujade, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2006
1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor XaDonald J P Pinto, Michael J Orwat, Mimi L Quan, et al.
The FEBS Journal|March 5, 2026
Metabolic thermodynamics: pertinent reference state and energy potentialsHans V Westerhoff, Barbara M Bakker, Andreas S Bommarius, et al.
Glycobiology|March 22, 2014
MIRAGE: the minimum information required for a glycomics experimentWilliam S York, Sanjay Agravat, Kiyoko F Aoki-Kinoshita, et al.
Standards in Genomic Sciences|February 10, 2011
Meeting Report from the Second "Minimum Information for Biological and Biomedical Investigations" (MIBBI) workshopCarsten Kettner, Dawn Field, Susanna-Assunta Sansone, et al.
Glycobiology|September 23, 2016
The minimum information required for a glycomics experiment (MIRAGE) project: sample preparation guidelines for reliable reporting of glycomics datasetsWeston B Struwe, Sanjay Agravat, Kiyoko F Aoki-Kinoshita, et al.
Plos One|February 25, 2015
Positive influence of being overweight/obese on long term survival in patients hospitalised due to acute heart failureSimona Littnerova, Jiri Parenica, Jindrich Spinar, et al.
Pageof 81